Want to see ADGM full AI Analyst Report?
ADGM Stock Chart & Stats
$1.08
-$0.11(-9.46%)
At close: 4:00 PM EST
$1.08
-$0.11(-9.46%)
Day’s Range― - ―
52-Week Range$0.51 - $2.58
Previous Close$1.04
Volume669.05K
Average Volume (3M)152.12K
Market Cap
$11.77M
Enterprise Value$36.72
Total Cash (Recent Filing)$12.91M
Total Debt (Recent Filing)$24.09M
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Aug 19, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside224.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress (PMA Filing)Submitting a PMA for the vCLAS system, backed by Breakthrough Device status, materially advances the pathway to U.S. commercial clearance. If approved, this creates a durable revenue channel into a large $5.8B VT market, supporting long‑term commercialization and scale.
Strong Pivotal Clinical ResultsRobust pivotal outcomes demonstrating high acute success, reduced ICD interventions and low major adverse events provide durable clinical credibility. Strong safety/effectiveness evidence supports physician adoption, reimbursement discussions and durable market penetration if commercialized.
Product Differentiation / Focused StrategyA specialized, purpose‑built VT ablation platform positions the company with a clear product moat versus generalist tools. Focused technology that simplifies procedures can sustain competitive advantage, broaden usable clinician base, and expand addressable market over time.
Bears Say
Minimal Revenue & Negative Gross ProfitThe firm has effectively no recurring sales and negative gross margins, indicating it has not yet commercialized at scale. This structural lack of revenue undermines ability to absorb fixed costs and means long‑term viability hinges on a successful, timely commercial launch and adoption.
Sustained Cash Burn And Negative FCFPersistent negative operating and free cash flow shows ongoing cash burn and dependence on external financing. Even with some improvement, continued negative FCF limits runway, risks dilution or higher borrowing costs, and constrains investments needed for commercial scaling.
Rising Leverage And Funding RiskLeverage has increased sharply to a debt‑to‑equity ratio near 4.2, heightening solvency and refinancing risk. Heavy debt reliance reduces financial flexibility, raises interest burden, and makes the company more vulnerable if product commercialization or subsequent fundraising underperforms expectations.
Adagio Medical Holdings News
ADGM FAQ
What was Adagio Medical Holdings’s price range in the past 12 months?
Adagio Medical Holdings lowest stock price was $0.51 and its highest was $2.58 in the past 12 months.
What is Adagio Medical Holdings’s market cap?
Adagio Medical Holdings’s market cap is $11.77M.
When is Adagio Medical Holdings’s upcoming earnings report date?
Adagio Medical Holdings’s upcoming earnings report date is Aug 19, 2026 which is in 32 days.
How were Adagio Medical Holdings’s earnings last quarter?
Adagio Medical Holdings released its earnings results on May 12, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.02.
Is Adagio Medical Holdings overvalued?
According to Wall Street analysts Adagio Medical Holdings’s price is currently Undervalued.
Does Adagio Medical Holdings pay dividends?
Adagio Medical Holdings does not currently pay dividends.
What is Adagio Medical Holdings’s EPS estimate?
Adagio Medical Holdings’s EPS estimate is -0.31.
How many shares outstanding does Adagio Medical Holdings have?
Adagio Medical Holdings has 22,210,459 shares outstanding.
What happened to Adagio Medical Holdings’s price movement after its last earnings report?
Adagio Medical Holdings reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -1.915%.
Which hedge fund is a major shareholder of Adagio Medical Holdings?
Currently, no hedge funds are holding shares in ADGM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adagio Medical Holdings
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
ADGM Stock 12 Month Forecast
Average Price Target
$3.50
▲(224.07% Upside)
Technical Analysis
Ownership Overview
45.47% Insiders
0.47% Mutual Funds
41.61% Other Institutional Investors
11.95% Public Companies and
Individual Investors